A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model

• Published in: International journal of molecular sciences 2024-07, Vol.25 (13), p.7410
• Main Authors: Bober, Aleksandra, Piotrowska, Anna, Pawlik, Katarzyna, Ciapała, Katarzyna, Maciuszek, Magdalena, Makuch, Wioletta, Mika, Joanna
• Format: Article
• Language: English
• Subjects: Analgesics; Analgesics - pharmacology; Analgesics - therapeutic use; Animals; CCR5 Receptor Antagonists - pharmacology; CCR5 Receptor Antagonists - therapeutic use; cenicriviroc; Chemokines; Chronic illnesses; Diabetes; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - drug therapy; Diabetic Neuropathies - drug therapy; Diabetic neuropathy; Disease Models, Animal; Drug dosages; Female; Females; Hyperalgesia - drug therapy; Imidazoles; Ligands; Male; Mice; Morphine; Morphine - pharmacology; Morphine - therapeutic use; Narcotics; neuropathic pain; Pain; Proteins; Receptors, CCR2 - antagonists & inhibitors; Receptors, CCR2 - metabolism; Receptors, CCR5 - genetics; Receptors, CCR5 - metabolism; Spinal cord; Sulfoxides
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25137410

The ligands of chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are associated with the pathomechanism of neuropathic pain development, but their role in painful diabetic neuropathy remains unclear. Therefore, the aim of our study was to examine the function of these factors in the hypersensitivity accompanying diabetes. Additionally, we analyzed the analgesic effect of cenicriviroc (CVC), a dual CCR2/CCR5 antagonist, and its influence on the effectiveness of morphine. An increasing number of experimental studies have shown that targeting more than one molecular target is advantageous compared with the coadministration of individual pharmacophores in terms of their analgesic effect. The advantage of using bifunctional compounds is that they gain simultaneous access to two receptors at the same dose, positively affecting their pharmacokinetics and pharmacodynamics and consequently leading to improved analgesia. Experiments were performed on male and female Swiss albino mice with a streptozotocin (STZ, 200 mg/kg, i.p.) model of diabetic neuropathy. We found that the blood glucose level increased, and the mechanical and thermal hypersensitivity developed on the 7th day after STZ administration. In male mice, we observed increased mRNA levels of , , and , while in female mice, we observed additional increases in and levels. We have demonstrated for the first time that a single administration of cenicriviroc relieves pain to a similar extent in male and female mice. Moreover, repeated coadministration of cenicriviroc with morphine delays the development of opioid tolerance, while the best and longest-lasting analgesic effect is achieved by repeated administration of cenicriviroc alone, which reduces pain hypersensitivity in STZ-exposed mice, and unlike morphine, no tolerance to the analgesic effects of CVC is observed until Day 15 of treatment. Based on these results, we suggest that targeting CCR2 and CCR5 with CVC is a potent therapeutic option for novel pain treatments in diabetic neuropathy patients.